AR882 is an investigational selective uric acid transporter 1 inhibitor. The Food and Drug Administration (FDA) has granted Fast Track designation to AR882 for the treatment of clinically visible ...

man hands gout arthritis When lesinurad 400mg was added to febuxostat, significantly more patients achieved target sUA by Month 6 (76.1%; P In a Phase 3 trial, lesinurad combined with febuxostat ...

The characteristics of the sample are presented in Table 1 and Table 2. The average age was 60.9 years, and patients had been diagnosed an average of 12 years. Most were male (81%), and 38% were ...

PRINCETON, N.J., Aug. 5, 2024 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and tophaceous gout patients, today announced full ...

SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 ...

Gout in postmenopausal women can have an atypical presentation, with numerous subcutaneous tophi of the hands and acute arthritis predominantly involving the upper limbs. In this case, the diagnosis ...

— REDUCE 1 is a study running in parallel with REDUCE 2 to evaluate pozdeutinurad's efficacy in lowering serum urate (sUA) levels and resolution of target tophi in gout patients — SAN DIEGO, July 1, ...

Secondary carpal tunnel syndrome (CTS) caused by intratendinous tophaceous gout is rare. Preoperative diagnosis would be ...

GOUT - a condition which people commonly associate with a rich diet - is a disorder which causes painful attacks of arthritis in the joints of the foot, knee, ankle, hand and wrist and especially the ...